Search - tctmd.com

Displaying 261 - 280 of 299

Sort: Relevancy | Date

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Three

Shelley Wood

March 19, 2017

News Daily News

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

Todd Neale

March 15, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Daily News

Edwards Lifesciences Pauses Transcatheter Mitral Valve Study to Work Out Design Issues

Michael O'Riordan

February 07, 2017

News Conference News ISET 2017

Forging Into the Future: Debating the Merits of TAVR in Younger, Futile, and Lower-Risk Patients

Caitlin E. Cox

February 06, 2017

News Daily News

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

Michael O'Riordan

January 03, 2017

News Daily News

Leaflet Thickening, Valve Durability After Balloon-Expandable TAVR: Studies Offer New Insights

Todd Neale

December 26, 2016

News Opinion Editor's Corner TCT 2016

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

Shelley Wood

November 07, 2016

News Conference News TCT 2016

Midterm Durability of TAVR Valves: PARTNER, Other Studies Boost Confidence

Todd Neale

November 01, 2016

News Industry News TCT 2016

Long-Term Study Results Show that PFO Closure is More Effective Than Medical Management in Preventing Recurrent Stroke

November 01, 2016

News Conference News TCT 2016

Final RESPECT Data Support PFO Closure for Cryptogenic Stroke Prevention

Yael L. Maxwell

November 01, 2016

News Industry News

Five Year Echocardiogram Follow-Up Data Demonstrates Sustained Durability After Transcatheter Aortic Valve Replacement In High-Risk And Inoperable Patients

November 01, 2016

Presentation TCT 2016

Controversy 2. Global Clinical Trial Experiences on Bioprosthetic Leaflet Thickening/Thrombosis: Updates and Insights

Presenter: Raj Makkar, Lars Sondergaard

October 31, 2016

Presentation TCT 2016

TCT 79: Course of Early Subclinical Leaflet Thrombosis After Transcatheter Aortic Valve Replacement With or Without Oral Anticoagulation

Presenter: John M. Lasala, Philippe Pibarot, Jürgen Rothe

October 31, 2016

Presentation TCT 2016

Leaflet Thickening, Dysfunction, and Thrombosis: Clinical Perspectives- Are Problems Under-Reported? Are the Changes a Class Effect?

Presenter: Carlos E. Ruiz, Ulrich Steinseifer, Raj Makkar

October 30, 2016

Presentation TCT 2016

Leaflet Thickening, Dysfunction, and Thrombosis: Latest Recommendations by the ISO Cardiac Valves Committee

Presenter: Carlos E. Ruiz, Ulrich Steinseifer

October 30, 2016

Presentation TCT 2016

Case #3: Leaflet Thrombosis Following Transcatheter Valve-in-Valve: Could It Have Been Prevented?

Presenter: Stanley J. Chetcuti, Susheel K. Kodali, Isaac George

October 30, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2016

Shelley Wood

September 30, 2016

News Conference News PCR London Valves 2016

TAVR vs SAVR: Limitations and Risks Debated as Transcatheter Therapies Move Into Younger and Lower-Risk Patients

Shelley Wood

September 20, 2016

Advertisement

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Live From Washington: ACC 2017, Day Three

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Edwards Lifesciences Pauses Transcatheter Mitral Valve Study to Work Out Design Issues

Forging Into the Future: Debating the Merits of TAVR in Younger, Futile, and Lower-Risk Patients

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

Leaflet Thickening, Valve Durability After Balloon-Expandable TAVR: Studies Offer New Insights

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

Midterm Durability of TAVR Valves: PARTNER, Other Studies Boost Confidence

Long-Term Study Results Show that PFO Closure is More Effective Than Medical Management in Preventing Recurrent Stroke

Final RESPECT Data Support PFO Closure for Cryptogenic Stroke Prevention

Five Year Echocardiogram Follow-Up Data Demonstrates Sustained Durability After Transcatheter Aortic Valve Replacement In High-Risk And Inoperable Patients

Controversy 2. Global Clinical Trial Experiences on Bioprosthetic Leaflet Thickening/Thrombosis: Updates and Insights

TCT 79: Course of Early Subclinical Leaflet Thrombosis After Transcatheter Aortic Valve Replacement With or Without Oral Anticoagulation

Leaflet Thickening, Dysfunction, and Thrombosis: Clinical Perspectives- Are Problems Under-Reported? Are the Changes a Class Effect?

Leaflet Thickening, Dysfunction, and Thrombosis: Latest Recommendations by the ISO Cardiac Valves Committee

Case #3: Leaflet Thrombosis Following Transcatheter Valve-in-Valve: Could It Have Been Prevented?

TCTMD’s Top 10 Most Popular Stories for September 2016

TAVR vs SAVR: Limitations and Risks Debated as Transcatheter Therapies Move Into Younger and Lower-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content